Screener
Rigel Pharmaceuticals RIGL Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
| Net income per share | ||
| Basic | $0.47 | $0.64 |
| Diluted | $0.44 | $0.63 |
| Weighted average shares used in computing net income per share |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's net income?
- Rigel Pharmaceuticals (RIGL) reported net income of $8.65M in Q1 2026.
- How has Rigel Pharmaceuticals's net income changed year-over-year?
- Rigel Pharmaceuticals's net income decreased by 24.4% year-over-year, from $11.45M to $8.65M.
- What is the long-term trend for Rigel Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's net income has grown at a 112.8% compound annual growth rate (CAGR), from -$17.91M to $367.02M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Rigel Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude